BioTuesdays

Tag - RAPT

RAPT-Therapeutics

SVB Leerink starts RAPT Therapeutics at OP; PT $49

SVB Leerink launched coverage of RAPT Therapeutics (NASDAQ:RAPT) with an “outperform” rating and a $49 price target. The stock closed at $33.07 on Aug. 11. RAPT is a clinical-stage biopharmaceutical company developing...

RAPT-Therapeutics

Cantor ups RAPT Therapeutics PT to $71 from $51

Cantor Fitzgerald raised its price target for RAPT Therapeutics (NASDAQ:RAPT) to $71 from $51, citing an increased probability of success for RPT193 in atopic dermatitis to 50% from 25% previously, and taking up peak...